Search results
ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
Clinical Trials Arena via Yahoo Finance· 6 hours agoFrom the dose level 1 cohort, there was one case of dose-limiting toxicity of febrile neutropenia....
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF...
WKRN Nashville· 4 days agoFood and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the ...
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
Zacks via Yahoo Finance· 1 day agoData from the same showed that treatment with Descartes-08 was generally well-tolerated, with no...
Zydus Lifesciences concludes subject enrolment in Phase II ALS trial
Clinical Trials Arena via Yahoo Finance· 5 hours agoThe company has already established Phase II proof-of-concept in cryopyrin-associated periodic...
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
Zacks via Yahoo Finance· 1 day agoHI-Bio has plans to advance felzartamab into phase III for all indications. HI-Bio has received...
Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
Market Watch· 2 days agoThe drug has received Breakthrough Therapy Designation and Orphan Drug Designation from the U.S....
Biogen to acquire HI-Bio for up to $1.8 billion By Investing.com
Investing.com· 2 days agos portfolio in immunology and rare diseases. HI-Bio's lead asset, felzartamab, is an anti-CD38...
Biogen enters deal to acquire HI-Bio for $1.8bn
Pharmaceutical Technology via Yahoo Finance· 1 day agoThe US Food and Drug Administration previously awarded breakthrough therapy and orphan drug (ODD) designations for felzartamab to treat ...
SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX...
FOX 23 News Albany· 3 days agoSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...
Biogen to Buy Human Immunology Biosciences for Up to $1.8 Bln
Market Watch· 2 days agoBiogen is buying the privately-held biotechnology company Human Immunology Biosciences for as much as $1.8 billion in a move to expand its immunology portfolio with an asset that is in late ...
